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Abstract 
A simple and selective LC method is described for the determination of AXITINIB dosage 
forms. Chromatographic separation is observed on a c18 packing column using mobile phase 
with a mixture of TEA -Acetonitrile (50:50) with detected at 254nm. Linearity was observed 
in the range 15-45 µg /ml for AXITINIB (r
2
 =0.997) for drug estimated by the proposed 
methods was in good agreement with the label claim. The proposed method was validated. 
The accuracy of the methods was assessed by recovery studies at three different levels. The 
current study indicated the absence of interference of commonly encountered pharmaceutical 
additives. The method was precise to be indicated by the repeatability analysis, by showing 
%RSD > 2. All statistical data proved the validity of the methods and used for routine 
analysis of pharmaceutical dosage form. 
 
Keywords:  axitinib, RP-HPLC, validation. 
 
INTRODUCTION 
A drug intended for internal or external 
use for diagnosis, treatment, mitigation or 
prevention of disease or disorder in human 
beings or animals and manufactured 
exclusively in accordance with the 
formulae mentioned in authoritative books. 
 
Quantitative analysis techniques are 
mainly used to determine the amount or 
concentration of analyte in a sample and 
expressed as a numerical value in 
appropriate units. These techniques are 
based on suitable chemical reaction and 
either measuring the amount of reagent 
added to complete the reaction or 
measuring the amount of reaction product 
obtained the characteristic [1, 2] 
movement of a substance through a 
defined medium under controlled 
conditions, electrical measurement or 
measurement of spectroscopic properties 
of the compound. Qualitative analysis is 
performed to establish composition of a 
substance. It is done to determine the 
presence of a compound or substance in a 
given sample or not. The various 
qualitative tests are detection of evolved 
gas, limit tests, color change reactions, 
determination of melting point and boiling 
point, mass spectroscopy, determination of 
nuclear half-life etc. 
 
Pharmaceutical analysis is a branch of 
chemistry involving a process of 
identification, determination, quantification, 
purification and separation of components in 
a mixture or determination of chemical 
structure of compounds. There are two main 
types of analysis – Qualitative and 
Quantitative analysis. Types of HPLC [15, 
16] HPLC is classified into various types 
 
Based on polarity of stationary and 
mobile phase 
   Normal Phase Chromatography 
 Reverse Phase Chromatography 
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Based on the principle of separation 
 Adsorption Chromatography 
 Partition Chromatography 
 Ion Pair Chromatography 
 Size Exclusion Chromatography 
 Chiral Phase Chromatography 
 
Based on elution technique 
 Isocratic Elution 
 Gradient Elution 
 
Based on scale of operation 
 Analytical HPLC 
 Preparative HPLC 
 
Based on the polarity of the stationary 
phase and the mobile phase, it is of two 
types: 
Normal Phase (NP) HPLC 
In this type, the stationary phase is polar, 
and the mobile phase is non-polar, polar 
compounds are retained for a longer period 
because of more affinity towards the 
stationary phase, hence non-polar 
compounds travel faster and are eluted 
first. 
Reverse Phase (RP) HPLC 
 
In this type, the stationary phase is non-
polar, and the mobile phase is polar, non- 
polar compounds are retained for longer 
periods as they have more affinity towards 
the stationary phase. Hence, polar 
compounds travel faster and are eluted 
first [2] 
 
Table 1: Types of HPLC based on polarity of stationary phase and mobile phase. 
Types Normal Phase Reverse Phase 
Stationary phase Polar Non polar 
Mobile phase Non polar Polar 
Compound eluted first Non polar Polar 
Compound eluted last Polar Non polar 
 
Instrumentation of HPLC 
The main components of HPLC are as 
given below and are schematically 
represented  
1. Solvent Reservoir 
2. Solvent Delivery System (Pump) 
3. Injection Port/ Auto sampler 
4. Column 
5. Detector 
6. Data Acquisition system 
7.  
 
Figure 2:  Schematic diagram of instrumentation of HPLC [18]. 
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DRUG PROFILE 
INTRODUCTION TO DRUG: [3] 
Axitinib 
Axitinib is an oral, potent, and selective 
inhibitor of vascular endothelial growth 
factor receptors (VEGFR) 1, 2, and 3. 
Axitinib is marketed with trade name 
Inayat®,  
Structure: 
 
 
Categories: 
 Antineoplastic and Immunomodulating 
Agents 
 Cytochrome P-450 CYP1A2 
Substrates 
 Cytochrome P-450 CYP2C19 
Substrates 
 Cytochrome P-450 CYP3A4 
Substrates 
 Enzyme Inhibitors 
 
Iupac Name: [4, 5] 
N-methyl-2-({3-[(E)-2-(pyridin-2-yl) 
Ethelyn]-2H-indazol-6-yl} sulfanyl) 
benzene-1-carboximidic acid 
 
Molecular weight 
386.47 
Chemical formula 
C22H18N4OS 
 
Mechanism of Action 
Axitinib acts to mechanize in blocking the 
tyrosine kinase receptors (VEGFR-1, 
VEGFR-2, and VEGFR-3). 
VEGFR- (vascular endothelial growth 
factor receptor). 
 
Pharmacodynamics: 
The Axitinib prevents the progression of 
cancer by inhibiting blocking tumor 
growth. And Angiogenesis 
 
Indication: Used in kidney cell cancer and 
investigated for use/treatment in pancreatic 
and thyroid cancer. 
MATERIALS AND METHODS [6, 7] 
                                                             Table 1: Instruments used. 
UV-Visible Spectrophotometer Nicolet evolution 100 
HPLC Shimadzu (LC 20 AT VP) 
HPLC Agilent 1200 series 
Ultra sonicator Citizen, Digital Ultrasonic Cleaner 
pH meter Global digital 
Electronic balance Shimadzu 
Syringe Hamilton 
HPLC Column INERTSIL column, C18(150x4.6 ID) 5µm 
 
Table 2: Reagents used. 
Water HPLC Grade 
Methanol HPLC Grade 
Potassium Dihydrogen ortho Phosphate AR Grade 
Acetonitrile HPLC Grade 
Ammonium acetate AR Grade 
Tetra Hydro Furan AR Grade 
 
Table 3: Drug used. 
Axitinib Gift Samples obtained from Chandra labs, Hyd. 
INLYTA (5mg) Obtained from local pharmacy 
 
 
 
 
 
31 Page 28-42 © MAT Journals 2019. All Rights Reserved 
 
Research & Review: Drugs and Drugs Development  
Volume 1 Issue 2 
Mobile Phase [7, 8] 
A mixture of 50 volumes of Triethylamine 
buffer pH 3.5 and 50 volumes of 
Acetonitrile was Prepared.  10 mins is the 
time duration for the mobile phase to 
sonicate and to remove the gases. 
 
METHOD DEVELOPMENT AND 
VALIDATION 
Introduction to Method Development 
[9,10] 
New Drugs introduced to the market is 
raising high statistically every year. These 
drugs may be of either new entities or 
partial structurally modified one. Often a 
time lag exists from the date of 
introduction of a drug into the market to 
the date of its inclusion in 
pharmacopoeias. It happened because of 
the possible uncertainties in the 
continuation and wider usage of these 
drugs, reports of new toxicities (resulting 
in their withdrawal from the market), 
development of patient resistance and 
introduction of better drugs by 
competitors. Under these conditions, 
standards and analytical procedures for 
these drugs may not be available in the 
pharmacopoeias. It becomes necessary, 
therefore, to develop newer analytical 
methods for such drugs. 
 
Analytical methods were used to maintain 
good manufacturing practice (GMP) and 
good laboratory practice (GLP) proceeded 
according to International conference of 
Harmonization (ICH) guidelines 
 
Method development is a continuous 
process that progresses in parallel with the 
evolution of the drug product. They should 
be suitable to support preclinical safety 
evaluations, pre-formulation studies, and 
prototype product stability studies. As 
drug development progresses, the 
analytical methods are refined and 
expanded, based on increased API and 
drug product knowledge. The methods are 
robust and uncomplicated, where they 
meet the appropriate regulatory guidelines. 
Scouting experiments are frequently 
performed during method development to 
establish the performance limits of the 
method, mainly for validation of 
experiments. These may include forced 
degradation studies, which are an integral 
part of the development of a stability-
indicating method. API is subjected to 
degradation by acid, base, peroxide, heat, 
and light. This allows for a determination 
of the capability of the method to separate 
and quantify degradation products while 
providing in the main mechanisms of 
degradation. Once a stability-indicating 
method is placed in the formulated drug 
product can then be subjected to heat and 
light in order to evaluate the potential 
degradation of the API in the presence of 
formulation excipients. Need for the  
 
Development of a New Method [11, 12] 
Several reasons are available for the 
development of a new method of analysis. 
 Existing methods may be too 
erroneous, artefact and/or 
contamination prone, or they may be 
unreliable (having poor accuracy or 
precision). 
 Existing methods may be too 
expensive, time consuming, or energy 
intensive, or they may not be easily 
automated. 
 Newer instrumentation and techniques 
may have evolved that provide 
opportunities for improved methods, 
including analyte identification or 
detection limits, greater accuracy or 
precision, or better return on 
investment. 
 There may be a need for alternative 
method to confirm, for legal or 
scientific reasons, analytical data 
originally obtained by existing 
methods. 
 
Method Development Using HPLC [13, 
14] in method development, an attempt to 
select the best chromatographic conditions 
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like the best column, the best mobile 
phase, the detection wavelength etc. to be 
used for routine analysis of any drug is 
done. For the method development by 
HPLC method some information about the 
sample is very essential i.e. number of 
components present in the sample, pKa 
values of different components, UV-
Visible Spectra of each analyte, solubility 
in different solvents, concentration range 
of each component, nature of sample etc. 
Prior to method development there must 
be some technical information i.e. 
chromatography method selection 
according to the sample properties, the 
sample when analyzed with HPLC, the 
condition where all compounds elute in a 
reasonable time, optimization of HPLC 
method with regard to analysis time, 
resolution, selectivity and sensitivity. 
 
Analyte Standard Characterization [15] All 
the information about the analyte is 
gathered regarding the structure, physical 
and chemical properties, toxicity, purity, 
hygroscopicity, solubility and stability. 
The availability of the 100% pure standard 
analyte is determined along with its 
storage and disposal information. If 
multiple components are to be analyzed in 
a sample matrix, the number of 
components to be analyzed is noted and 
the availability of the standard for each 
component is checked. 
 
Literature Search and Prior Methodology 
[16] the available literature is searched for 
all types of information related to the 
analyte. Availability of information 
regarding the synthesis, physical and 
chemical properties, solubility or relevant 
analytical methods is determined. Books, 
periodicals, regulatory agency compendia, 
such as IP, USP/NF, BP etc. should be 
referred. Chemical Abstracts Service 
(CAS) automated/ computerized literature 
searches also should be used. 
 
Information pertaining to prior analytical 
work on the analyte has to be determined 
within the company and compile the 
available data, results, reports, memos and 
publications. 
 
Choosing a Suitable Method Using the 
available literature and previous 
methodology, the methods are adapted and 
modified. Sample preparation and 
instrument conditions are adopted to make 
use of the latest methods and 
instrumentation. Usually a compound with 
analytical method exists that is similar to 
the analyte of interest. 
Optimization 
 
Choice of method [9] 
The most commonly used 
chromatographic methods are normal 
phase chromatography, reverse phase 
chromatography, reverse phase ion-pair 
chromatography and ion-exchange 
chromatography. In the selection of 
suitable chromatographic method for 
organic compounds, first reversed phase 
should be tried, if not successful, normal 
phase should be tried, then reverse phase 
ion-pair chromatography should be tried, 
ion-exchange chromatography at the end. 
 
Choice of Mobile Phase 
Selection of mobile phase is very 
important in the analysis of the drug in 
reversed phase chromatography. We can 
use acetonitrile frequently as it is suitable 
for the entire UV range, methanol and 
Isopropanol are not suitable below 
wavelength of 210nm, acetic acid is 
suitable above a wavelength of 240 nm, 
for the preparation of buffers, both 
K2HPO4and KH2PO4can be used in entire 
UV range, freshly distilled THF is suitable 
for HPLC above a wave length of 240nm, 
TEA is suitable above 240 nm, ammonium 
acetate can be used above 215 nm, EDTA 
can be used in entire UV range, sodium 
phosphate is suitable above 210 nm. 
 
The required organic phase concentration 
for the mobile phase is estimated by 
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gradient elution method. For aqueous 
simple mixtures, the simple way to start is 
with gradient in reversed phase 
chromatography. Gradient can be started 
with 10% organic phase in the mobile 
phase and organic phase concentration 
(Methanol & Acetonitrile) can be 
increased up to 100% within 20-60 min. 
Separation can then be optimized by 
changing the initial mobile phase 
composition according to the 
chromatogram obtained from preliminary 
run. The initial mobile phase composition 
can be estimated on the basis of where the 
compounds of interest were eluted, at what 
mobile composition. 
 
Changing the polarity of the mobile phase 
can alter the elution of drug molecules. 
The elution strength of a mobile phase is 
dependent on its polarity, the stronger the 
polarity, higher is the elution. Ionic 
samples (acidic or basic) can be separated, 
if they are presented in un-dissociated 
form. Dissociation of ionic samples may 
be suppressed by proper selection of ph. 
 
The pH of the mobile phase has to be 
selected in such a way that the compounds 
are not ionized. If the retention time is too 
short, the decrease of the organic phase 
concentration in the mobile phase is of 
5%. If the retention times are too long, an 
increase in 5% steps of the organic phase 
concentrations is needed. 
When separating acid or bases, buffered 
mobile phase is required to maintain 
consistency in retention time and 
selectivity. Buffered salts reduce peak 
tailing for basic compounds by effectively 
masking silanol groups and also reduce 
potential ion- exchange interactions with a 
protonated silanol groups. As potassium is 
a stronger counter ion than sodium, it 
provides improved results compared to 
sodium (Na
+
). Potassium phosphate is 
used for preparation of buffers of various 
pH. If band tailing is observed for basic 
amphoteric compounds few drops of 
diluted triethylamine or ammonium acetate 
is added, for acidic or amphoteric 
compounds, few drops of diluted 
triethylamine or ammonium acetate is 
tried. For neutral compounds, the aqueous 
eluent used in method development is 
water, for weak to medium acidic 
compounds, 100 mM H3PO4 buffer of pH 
2.3, for weak to medium basic or acidic 
compounds in ionized form 100mM 
H3PO4 buffer of pH 4.0, 50 mM 
H3PO4buffer of pH 7.5 are used. Unknown 
sample should be analyzed first with 
water, then with an acidic and a neutral 
buffer. [7] 
 
Choice of Column 
Columns being the heart of HPLC for 
optimum separation, Stable, high 
performance column with good selectivity, 
efficiency is essential requirement for 
rugged and reproducible method. These 
characteristics are dependent on the 
columns manufacturer’s production of 
good quality columns and packing 
materials. 
Column length 
 Longer columns are chosen for 
increased resolution. 
 Shorter columns are chosen for shorter 
analysis time, lower back pressure, fast 
equilibration and less solvent 
consumption. 
 
Column internal diameter 
 Wider diameter columns are chosen for 
greater sample loading. 
 Narrow columns are chosen for more 
sensitivity and reduced mobile phase 
consumption. 
 
Particle shape 
 Columns with spherical particle shapes 
are preferred when lower back pressure 
column stability and greater efficiency 
is required. 
 Columns with irregular particle shapes 
are preferred when large surface area 
and high capacity is required. 
 
Particle size 
 Columns with small particle size of 3 - 
4 μm are preferred for complex 
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mixtures with similar components. 
Combination of a short column (10- 50 
mm) with small particle size is used for 
fast, high resolution separations. 
 Columns with larger particle size of 5 
– 10 μm are preferred for structurally 
different compounds. 
 Columns with large particle of 15 – 
20 μm are used for preparative 
separations. 
 
Surface area 
 Columns with high surface area 
packing are selected for more capacity, 
greater resolution and longer retention. 
 Columns with low surface area 
packing are selected for quicker 
equilibration time. 
 
Carbon load 
 Columns with high carbon load are 
chosen for greater column capacities 
and resolution. 
 Columns with low carbon load for 
faster analysis time. 
 
a) Choice of Detector 
Detectors are eyes of the liquid 
chromatography system and measure the 
compounds after their separation on the 
column. Selected detector should be 
capable of responding to change in 
concentrations of all the components in the 
sample with adequate sensitivity even to 
measure trace substances. The detectors 
must have certain characteristics i.e. high 
sensitivity, higher linear dynamic range, 
application to most of the solutes, does not 
contribute to band broadening, non-
destructive, faster response. 
Further Optimization [8] 
 
After the selection of a suitable method, 
mobile phase, column and detector, further 
optimization can be done to obtain a well-
developed method. 
 
For shorter analysis time 
 Change to isocratic method. The 
suitable mobile phase composition is 
estimated from the gradient run. 
 Use of shorter column, if proper 
resolution is obtained. 
For better resolution 
 Use of longer column. 
 Use of stationary phase with smaller 
particles (3 – 4 μm). 
For better selectivity and sensitivity 
 Other stationary phases e.g. phenyl, 
CN etc. 
 pH control with ion-forming 
compounds 
 Use of methanol or THF instead of 
acetonitrile. 
 Detection at the absorption maximum 
of the substance 
 All factors which lead to narrower and 
higher peaks as gradient elution, 
smaller particle, micro bore columns.
 
 
Figure 3: Outline of the process involved in method development. 
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Parameters Affecting Changes in 
Chromatograph [11] 
The various parameters affecting the 
changes in chromatographic conditions are 
1. Flow rate 
2. Temperature 
3. pH 
4. Ion pair reagent 
5. Column efficiency 
6. Capacity factor 
7. Resolution 
8. Retention time 
9. Peak asymmetry 
Introduction to Method Validation 
Validation is an integral part of quality 
assurance; it involves the systematic study 
of systems, facilities and processes aimed 
at determining whether they perform their 
intended functions adequately and 
consistently as specified. Validation itself 
does not improve processes it should have 
been properly developed and are under 
control. 
 
Method validation is defined as the 
process of proving that an analytical 
method is acceptable for its intended use. 
To ensure compliance with quality and 
safety standards, the United States, 
Europe, Japan, and other countries have 
published compendia, or pharmacopeias, 
that describe official test methods for 
many marketed drug products. For 
example, analytical methods found in 
United States Pharmacopeia (USP) are 
legally recognized analytical procedures 
under section 501 (b) of the Federal Food, 
Drug, and Cosmetic Act. A great deal of 
effort has been devoted to the 
harmonization of pharmaceutical 
regulatory requirements in the United 
States, Europe, and Japan. The recent FDA 
methods validation draft guidance 
documents as well as U.S. both refer to 
ICH guidelines. 
 
The required validation parameters, also 
termed analytical performance 
characteristics or analytical figs of merit. 
Methods should be validated or 
revalidated. Quantitative tests of the active 
moiety in samples of drug substance or 
drug product or other selected 
component(s) in the drug product. 
 
Method Validation (ICH Guidelines) [14] 
1. Accuracy, 
2. Precision, 
 Repeatability, 
 Intermediate precision. 
3. Specificity / Selectivity, 
4. Limit of Detection, 
5. Limit of Quantitation, 
6. Linearity, 
7. Range, 
8. Robustness, 
9. System Suitability. 
 
Table 4: Acceptance Limits for System Suitability Test. 
Parameter Limit 
Capacity Factor k’> 2 
Injection precision RSD < 1% for n ≥ 5 
Resolution Rs> 2 
Tailing factor As ≤ 2 
Theoretical plates N> 2000 
 
RESULTS AND DISCUSSION  
Solubility Studies 
These studies are carried out at 25 
0
 C 
AXITINIB: It is poorly soluble in water 
(1.0 mg/100 mL) and in aqueous solutions 
at low pH (0.1 mg/100 mL at pH 1.1 and 
4.0; 0.2 mg/100 ml at pH 5.0). Solubility 
increases at higher pH values (in such  
where the preparations with 43 mg/100 
mL at pH 7.5). 
Determination of Working Wavelength 
(λmax) 
In estimation of drug, wavelength is used. 
Preparation of standard stock solution of 
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AXITINIB 10mg of AXITINIB was 
weighed and transferred in to 100ml 
volumetric flask and dissolved in methanol 
and then make up to the mark with 
methanol and prepare 10 µg /ml of 
solution by diluting 1ml to 10ml with 
methanol. 
 
Results- The wavelength of maximum 
absorption (Zmax) of the drug, 100 µg/ml 
solution of the drug in methanol were 
scanned using UV-Visible spectrophotometer 
within the wavelength region of 200–400 nm 
against methanol as blank. The resulting 
spectra are shown in the fig. no. 8.1, 8.2 and 
8.3 and the absorption curve shows 
characteristic absorption maxima at 254nm 
for AXITINIB  
 
.  
Figure 4: UV-VIS spectrum of AXITINIB. 
 
Observation: Zmax was found to be 254 
nm for AXITINIB shown in the figure 
 
METHOD DEVELOPMENT OF 
AXITINIB. Trial - 1 
Chromatographic conditions 
Mobile phase : Mixed phosphate buffer: 
ACN (55:45) Column  : Zodiac, 
C18 (250×4.6× 5µ) 
wavelength : 254 nm 
Flow rate : 1ml/min 
Preparation of mixed standard solution 
Weigh accurately 10 mg of AXITINIB in 
100 ml of volumetric flask and dissolve in 
100ml of mobile phase and make up the 
volume with mobile phase from above 
stock solution 30 µg/ml of AXITINIB is 
prepared by diluting 3ml to 10ml with 
mobile phase. This solution is used for 
recording chromatogram. 
 
Observation: The Asymmetry was not 
satisfactory for AXITINIB (Asymmetry 
more than 2 and greater than
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Trial- 2 
Chromatographic conditions 
Mobile phase : ACN: Water (40:60) 
Column : Zodiac, C18 (250×4.6× 
5µ) 
Wavelength : 254nm 
Flow rate : 1.2 ml/min 
Preparation of mixed standard solution 
Weigh accurately 10 mg of AXITINIB in 
100 ml of volumetric flask and dissolve in 
100ml of mobile phase and make up the 
volume with mobile phase From above 
stock solution 30 µg/ml of AXITINIB is 
prepared by diluting 3ml to 10ml with 
mobile phase. This solution is used for 
recording chromatogram. 
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Observation: The Asymmetry for 
AXITINIB was more than 2.0. The 
efficiency of AXITINIB was less than 
2000. The details are given in the table 
8.3.2 and figure 8.3.2, Hence it was not 
taken for optimization. 
Trial- 3: 
 
Chromatographic conditions 
Mobile phase : Mixed phosphate  
Buffer      : ACN +methanol (20+50+30)  
Column    : Zodiac, C18 (250×4.6× 5µ) 
Wavelength : 254nm 
Flow rate : 1ml/min 
Preparation of mixed standard solution 
Weigh accurately 10 mg of AXITINIB in 
100 ml of volumetric flask and dissolve in 
100ml of mobile phase and make up the 
volume with mobile phase From above 
stock solution 30 µg/ml of AXITINIB is 
prepared by diluting 3ml to 10ml with 
mobile phase. This solution is used for 
recording chromatogram. 
Chromatogram of AXITINIB by using 
mobile phase 
Observation: 
The Efficiency of AXITINIB was very 
less. Asymmetry was more
 
 
Trial - 4: 
Chromatographic conditions 
Mobile phase : TEA+ACN 
Ratio : 50:50 
Column : Zodiac, C18 (250×4.6× 5µ) 
Wavelength : 254 nm 
Flow rate : 1ml/min 
pH : 3.5 
Preparation of mixed standard solution 
Weigh accurately 10 mg of AXITINIB in 100 ml of volumetric flask and dissolve in 100ml 
of mobile phase and make up the volume with mobile phase From above stock solution 30 
µg/ml of AXITINIB is prepared by diluting 3ml to 10ml with mobile phase. This solution is 
used for recording chromatogram. 
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Chromatogram of AXITINIB by using mobile phase. 
Observation: 
The peak efficiency was more than 2000. The peak tailing factor was less than 2.0. 
The resolution between peaks was more than 1.5 
Optimized chromatographic conditions 
Assay 
Assay Results 
 
AXITINIB  
 Standard Area Sample Area 
Injection-1 2526136 2517760 
Injection-2 2515827 2527548 
Injection-3 2510709 2516884 
Injection-4 2525250 2495644 
Injection-5 2523113 2497496 
Injection-6 2526637 2507449 
Average Area 2521278.67 2510463.5 
Assay(%purity) 99.5710444 
Observation 
The amount of AXITINIB present in the taken dosage form was found to be 90% and 110% 
respectively. 
Results for Method precision of AXITINIB 
 
Mobile phase Triethylamine: Acetonitrile (50:50) 
Column Zodiac, C18 (250×4.6× 5µ) 
Flow rate 1.0 ml/min 
Column temperature Room temperature(20-25oC) 
Sample temperature Room temperature(20-25oC) 
Wavelength 254nm 
Injection volume 20 µl 
Run time 8 min 
Retention time About 3.075 
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AXITINIB 
S.No. Rt Area 
1 3.107 2073796 
2 3.025 2036834 
3 3.085 2078955 
4 3.078 2075109 
5 3.098 2063159 
6 3.079 2075519 
average 3.07867 2067229 
Study 0.02863 15823.2 
%RSD 0.92983 0.76543 
Observation: Test results for AXITINIB was showing that the %RSD of Assay results are 
within limits 
 
Result of Robustness study 
Parameter 
AXITINIB 
Retention time(min) Area 
Flow   
1.0ml/min 3.671 2589974 
1.4ml/min 2.696 1891623 
Wavelength   
252nm 3.081 2113775 
256nm 3.086 2154238 
 
Observation: From the observation it was found that the system suitability parameters were 
within limit at all variable conditions. 
 
Results for Ruggedness 
AXITINIB %Assay 
Analyst 01 99.07325 
Analyst 02 99.79389 
 
Observation: From the observation the 
%RSD between two analysts Assay values 
were not greater than 2.0%, hence the 
method is rugged. 
 
SUMMARY 
A simple and selective LC method is 
described for the determination of 
AXITINIB dosage forms. 
Chromatographic separation was achieved 
on a c18 column using mobile phase 
consisting of a mixture of Triethylamine 
Buffer: Acetonitrile (50:50) with detection 
of 254nm. Linearity was observed in the 
range 15-45 µg /ml for AXITINIB (r
2
 
=0.997) for drug estimated by the 
proposed methods was in good agreement 
with the label claim. 
 
The proposed method was validated. The 
accuracy of the methods was assessed by 
recovery studies at three different levels. 
Showing %RSD less than. All statistical 
data proves validity of methods and can be 
used for routine analysis of pharmaceutical 
dosage form 
 
CONCLUSION 
From the above experimental results and 
parameters it was concluded that, this 
newly developed method for the 
estimation of AXITINIB was found to be 
simple, precise, accurate  and high 
resolution and lower retention time makes 
this method more acceptable and effective 
and it can be applied for routine analysis in 
research institutions for quality control 
department in industries, approved testing 
laboratories, bio-pharmaceutical and bio- 
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equivalence studies and in clinical 
pharmacokinetic studies in near future. 
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